Mostrar el registro sencillo del ítem

dc.contributor.authorSerrano-Villar, Sergio
dc.contributor.authorLopez-Huertas, Maria Rosa 
dc.contributor.authorJiménez, Daniel
dc.contributor.authorGalera, Carlos
dc.contributor.authorMartínez-Sanz, Javier
dc.contributor.authorMoreno, Elena
dc.contributor.authorMuriel, Alfonso
dc.contributor.authorGutiérrez, Félix
dc.contributor.authorBusca, Carmen
dc.contributor.authorPortilla, Joaquín
dc.contributor.authorBisbal, Otilia
dc.contributor.authorIribarren, José Antonio
dc.contributor.authorTejerina, Francisco
dc.contributor.authorde los Santos, Ignacio
dc.contributor.authorMoreno, Santiago
dc.contributor.authorCoRIS Cohort
dc.date.accessioned2022-05-24T11:00:15Z
dc.date.available2022-05-24T11:00:15Z
dc.date.issued2022-03-14
dc.identifier.citationFront Immunol. 2022 Mar 14;13:848630.es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/14485
dc.description.abstractBackground: Because inflammation is associated with mortality and has been linked to HIV transcription in lymphoid tissues during ART, it is necessary to address the long-term effects of switching 3-drug (3DR) to 2-drug regimens (2DR) on inflammation. Methods: Nested study in the Spanish AIDS Research Network. We selected PWH ART-naive initiating 3DR who achieved viral suppression in the first 48 weeks and either remained on 3DR or switched to 2DR (3TC+bPI; 3TC+DTG; DTG+RPV). We assessed the trajectories on inflammatory markers during ART using multivariate piecewise mixed models. Results: We analyzed 619 plasma samples from 148 patients (3DR, N=90; 2DR, N=58), the median follow-up was 4.6 (IQR 3.2-6.2) years. There were no significant differences in baseline characteristics between groups. After adjusting for potential confounders, patients with 3DR experienced a slow decline of IL6, hs-CRP, sCD14, sCD163, and D-dimer over time. In contrast, compared to 3DR, switching to 2DR was associated with increases in IL-6 (p=0.001), hs-CRP (p=0.003), and D-dimer (p=0.001) after year 3 from virologic suppression. 2DR was associated with a higher risk of hs-CRP quartile increase (aOR 3.3, 95%CI 1.1-10) and D-dimer quartile increase (aOR 3.7, 95%CI 1.1-13). The adjusted biomarker trajectories did not reveal a distinct pattern according to the type of 2DR used (bPI vs DTG). Conclusions: In this study in virally suppressed individuals, maintaining 3DR was associated with a more favorable long-term inflammatory profile than switching to 2DR. The potential clinical implications of these findings on the development of non-AIDS events deserve further investigation.es_ES
dc.description.sponsorshipThe HIV BioBank, integrated in the Spanish AIDS Research Network, is supported by Instituto de Salud Carlos III, Spanish Health Ministry (Grant n° proyectos RD06/0006/0035, RD12/0017/0037 and RD16/0025/0019) as part of the Plan Nacional R + D + I and co-financed by the European Development Regional Fund ‘‘A way to achieve Europe’’ (ERDF). The RIS Cohort (CoRIS) is funded by the Instituto de Salud Carlos III through the Red Temática de Investigación Cooperativa en SIDA (RIS C03/173, RD12/0017/0018 and RD16/0002/0006) as part of the Plan Nacional R+D+I and cofinanced by ISCIII-Subdirección General de Evaluacion and Fondo Europeo de Desarrollo Regional (FEDER)”. This work was supported by the Instituto de Salud Carlos III projects AC17/00019, PI18/00154, ICI20/00058, CIBER de Enfermedades Infecciosas, and Gilead Sciences (Investigator Sponsored Research ISR-17-10192). The funders had no role in the study design, data analysis, or in the interpretation of the results.es_ES
dc.language.isoenges_ES
dc.publisherFrontiers Media es_ES
dc.type.hasVersionVoRes_ES
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectHIVes_ES
dc.subjectAntiretroviral therapyes_ES
dc.subjectC reactive proteines_ES
dc.subjectD-dimeres_ES
dc.subjectInflammationes_ES
dc.titleLong-Term Changes of Inflammatory Biomarkers in Individuals on Suppressive Three-Drug or Two-Drug Antiretroviral Regimenses_ES
dc.typejournal articlees_ES
dc.rights.licenseAtribución 4.0 Internacional*
dc.identifier.pubmedID35359950es_ES
dc.format.volume13es_ES
dc.format.page848630es_ES
dc.identifier.doi10.3389/fimmu.2022.848630es_ES
dc.contributor.funderInstituto de Salud Carlos III es_ES
dc.contributor.funderMinisterio de Sanidad (España) es_ES
dc.contributor.funderPlan de Recuperación, Transformación y Resiliencia (España) es_ES
dc.contributor.funderUnión Europea. Fondo Europeo de Desarrollo Regional (FEDER/ERDF) es_ES
dc.contributor.funderRed de Investigación Cooperativa en Investigación en Sida (España) es_ES
dc.contributor.funderCentro de Investigación Biomédica en Red - CIBERINFEC (Enfermedades Infecciosas) es_ES
dc.contributor.funderGilead Sciences (Spain) es_ES
dc.description.peerreviewedes_ES
dc.identifier.e-issn1664-3224es_ES
dc.relation.publisherversionhttps://doi.org/10.3389/fimmu.2022.848630es_ES
dc.identifier.journalFrontiers in Immunologyes_ES
dc.repisalud.centroISCIII::Centro Nacional de Microbiologíaes_ES
dc.repisalud.institucionISCIIIes_ES
dc.rights.accessRightsopen accesses_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/ES/RD06/0006/0035es_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/ES/RD12/0017/0037es_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/ES/RD16/0025/0019es_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/ES/RISC03/173es_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/ES/RD12/0017/0018es_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/ES/RD16/0002/0006es_ES
dc.relation.projectFISinfo:eu-repo/grantAgreement/ES/AC17/00019es_ES
dc.relation.projectFISinfo:eu-repo/grantAgreement/ES/PI18/00154es_ES
dc.relation.projectFISinfo:eu-repo/grantAgreement/ES/ICI20/00058es_ES


Ficheros en el ítem

Acceso Abierto
Thumbnail
Acceso Abierto
Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución 4.0 Internacional
Este Item está sujeto a una licencia Creative Commons: Atribución 4.0 Internacional